Xuling Lin, Mei Lyn Carissa Lam, Ding Fang Chuang, Joanne Yong Ern Yuen, Liqing Fu, Valerie Jun Zhi Teh, Aynul Marliya, Seyed Ehsan Saffari, Christen Sheng Jie Lim, Yu-Lin Wong, Ying Hao Christopher Seet
{"title":"uSINE-PAMS Artificial Intelligence-Driven, Ultrasound-Guided Lumbar Puncture to Improve Procedural Accuracy: A Pilot Study Report.","authors":"Xuling Lin, Mei Lyn Carissa Lam, Ding Fang Chuang, Joanne Yong Ern Yuen, Liqing Fu, Valerie Jun Zhi Teh, Aynul Marliya, Seyed Ehsan Saffari, Christen Sheng Jie Lim, Yu-Lin Wong, Ying Hao Christopher Seet","doi":"10.1212/CPJ.0000000000200447","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Traditional lumbar punctures (LPs) often fail, leading to diagnostic delays and increased risks. Ultrasound guidance provides improved success rates but faces adoption barriers due to neuraxial-ultrasound training and implementation challenges. The Ultrasound-Guided Spinal Landmark Identification With Needle Navigation System and Position and Angular Marking System (uSINE-PAMS) were designed to address these issues: uSINE is a machine-learning software for neuraxial-ultrasound guidance; PAMS is a hardware that translates ultrasound data for accurate needle insertion.</p><p><strong>Recent findings: </strong>A pilot study with 10 patients showed that uSINE-PAMS-guided LP achieved an 80% first-pass success rate with no complication; the median patient age was 43 years, and the median body mass index was 24.5 kg/m<sup>2</sup>. The uSINE-PAMS system showed feasibility.</p><p><strong>Implications for practice: </strong>This pilot study showed that uSINE-PAMS-guided LP is feasible with a promising first-pass success rate at 80%. An ongoing phase 2 study (NCT05824546) of uSINE-PAMS may alter future standard of practice for LPs.</p><p><strong>Trial registration information: </strong>This pilot study is registered under ClinicalTrials.gov (ID: NCT05824546).</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 2","pages":"e200447"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975302/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200447","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Traditional lumbar punctures (LPs) often fail, leading to diagnostic delays and increased risks. Ultrasound guidance provides improved success rates but faces adoption barriers due to neuraxial-ultrasound training and implementation challenges. The Ultrasound-Guided Spinal Landmark Identification With Needle Navigation System and Position and Angular Marking System (uSINE-PAMS) were designed to address these issues: uSINE is a machine-learning software for neuraxial-ultrasound guidance; PAMS is a hardware that translates ultrasound data for accurate needle insertion.
Recent findings: A pilot study with 10 patients showed that uSINE-PAMS-guided LP achieved an 80% first-pass success rate with no complication; the median patient age was 43 years, and the median body mass index was 24.5 kg/m2. The uSINE-PAMS system showed feasibility.
Implications for practice: This pilot study showed that uSINE-PAMS-guided LP is feasible with a promising first-pass success rate at 80%. An ongoing phase 2 study (NCT05824546) of uSINE-PAMS may alter future standard of practice for LPs.
Trial registration information: This pilot study is registered under ClinicalTrials.gov (ID: NCT05824546).
期刊介绍:
Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.